Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC

PHASE1,PHASE2

Phase

RECRUITING

Status

Enrollment

OTHER_GOV

Sponsor class

Conditions

BIOLOGICAL: ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles)
BIOLOGICAL: ANOC-002 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles)
BIOLOGICAL: ANOC-003 (TCR-T cells targeting KRAS G12D mutation presented by specific HLA alleles)

Anocca AB